Highlights:

Biome Australia FY25 international revenue rose 69% YoY to approximately AUD 1.5 million.

BIO expanded distribution across Canada, UK, Ireland, and New Zealand during FY25.

BIO signed FY26 agreements with major wholesalers including Uniphar and Propharma.

Biome Australia Limited (ASX:BIO) has released a trading update highlighting its international business progress for the financial year ended 30 June 2025 (FY25). The company reported revenue of approximately AUD 1.5 million from international markets, marking a 69% increase from FY24. This performance reflects developments in sales networks, distributor partnerships, and initial market entry traction across Canada, the United Kingdom, Ireland, and New Zealand.

Biome develops and markets microbiome-based health products under brands including Activated Probiotics and Activated Therapeutics. The company’s strategy in FY25 focused on expanding its international sales presence through new market entries and distributor partnerships.

In Canada, initial demand for Activated Probiotics exceeded internal expectations, accelerating the brand’s rollout. Products are now available in prominent retail pharmacy groups such as Pure Pharmacy (British Columbia), Healthy Planet (national), Nature’s Emporium (Ontario), and Nature’s Signature (Ontario). The company also reported early engagement from the practitioner market, which it considers an important driver of repeat product recommendations and awareness among health professionals. To support operations, Biome appointed two Canada-based sales and education representatives and is preparing to launch additional products pending Health Canada approvals in FY26.

In Europe, Biome’s efforts in FY25 led to multiple distribution arrangements across Ireland and the UK. These include independent pharmacy and health food retailers such as Horans Health stores in Ireland and Planet Organic in the UK. The company also entered into a supply agreement with Uniphar, a leading European pharmaceutical wholesaler, in early FY26. This partnership is expected to facilitate access to major pharmacy chains in the region, with further rollout details to be disclosed in the coming months.

Biome also reported expansion in New Zealand through a distribution agreement signed in late Q4 FY25 with Propharma, a subsidiary of EBOS Group (ASX:EBO) and one of the country’s major pharmaceutical wholesalers. This partnership is expected to improve the availability of Biome’s product range through national pharmacy channels, building on the company's existing practitioner network in the country.

The international sales and education teams are coordinated from Biome’s Australian headquarters, which provides product training, brand consistency, and logistical support across regions. The company views this centralised structure as important for managing operations across multiple territories while maintaining messaging and supply chain alignment.

Biome's Managing Director and Founder, Blair Norfolk, acknowledged the team’s contributions and noted that FY25 was an important period for laying the groundwork for further expansion. He stated that international business development and distribution deals were major areas of focus and that early feedback from health professionals, retailers, and consumers had been encouraging.

Looking ahead, Biome expects to provide more detailed updates on product availability and distribution outcomes, particularly in connection with new partnerships in Europe and New Zealand. The launch of the Activated Therapeutics brand is expected to be part of the company’s evolving international offering, complementing its practitioner-focused approach.

BIO trading at 2.68% higher at AUD 0.58 per share as on 15 July 2025.